OncoQuest starts enrolment in Phase I/II ovarian cancer trial

Canada-based OncoQuest has started enrolling patients in a Phase I/II clinical trial to evaluate the combination of its antibody oregovomab with Hiltonol as a treatment for ovarian cancer.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news